GlassScriptPhysician profile
Paul Mark Baylon
NPI 1003824020
$1,683.23
in general payments reported to CMS, 2019-2025
15 companies · $573 in 2025
The $573 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $150 · 2021: $220 · 2022: $178 · 2023: $215 · 2024: $230 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $429.60 | 2019-2025 | Penmenvy, Bexsero |
| Organon LLC | $263.87 | 2021-2025 | Nexplanon |
| Shield Therapeutics INC | $184.05 | 2024-2025 | |
| Sanofi Pasteur INC. | $162.05 | 2022-2025 | |
| Pfizer INC. | $159.79 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $127.51 | 2019-2024 | Gardasil 9, Vaqta, Vaxneuvance |
| Cranial Technologies, INC | $112.90 | 2021-2025 | Doc Band |
| Hologic Sales and Service, LLC | $95.26 | 2020-2024 | Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $31.52 | 2025 | |
| Lilly USA, LLC | $26.39 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $23.29 | 2025 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $22.73 | 2023 | Slynd |
| Exact Sciences Corporation | $18.06 | 2025 | Cologuard Collection Kit |
| Phadia US INC. | $13.14 | 2021 | |
| Agile Therapeutics, INC. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Baylon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.